Scientists are exploring a potentially transformative approach to preventing or delaying Alzheimer’s disease, investigating whether anti-amyloid drugs can slow down or even prevent the onset of dementia.
The research focuses on clearing amyloid plaques, abnormal protein deposits that accumulate in the brain and are believed to play an important role in the development and progression of Alzheimer’s.
Although the findings remain preliminary, the possibility of intervening before significant cognitive decline occurs represents an important development in the global fight against the disease
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Alzheimer’s is one of the most challenging neurological conditions affecting older populations. It gradually damages memory, thinking abilities and behaviour, eventually making everyday activities increasingly difficult.
Approximately one in nine Americans aged 65 and older lives with Alzheimer’s, highlighting the enormous public health burden associated with the disease.
Beyond patients themselves, millions of family members and caregivers experience the emotional, financial and practical consequences of supporting people living with dementia.
Anti-amyloid treatments are attracting considerable scientific attention because they target one of the biological processes associated with Alzheimer’s.
Amyloid beta proteins can accumulate between brain cells, forming plaques that researchers believe contribute to the chain of events leading to neuronal damage. By removing these deposits, scientists hope to interrupt disease progression and preserve cognitive function for longer periods.
Recent advances in this treatment approach have strengthened interest in whether Alzheimer’s can be addressed before symptoms become severe.
Drugs such as lecanemab and donanemab have demonstrated that targeting amyloid can reduce plaque levels and modestly slow cognitive decline in certain patients with early-stage Alzheimer’s.
These developments have encouraged researchers to investigate whether administering treatments earlier, potentially before noticeable symptoms emerge, could deliver greater benefits.
However, important questions remain unanswered. Clearing amyloid plaques does not necessarily eliminate every biological process responsible for Alzheimer’s.
Other factors, including tau protein accumulation, inflammation, vascular damage and changes in brain metabolism, contribute to the disease. Researchers must establish whether removing amyloid early enough can meaningfully delay symptoms or prevent the condition from developing altogether.
Safety is another significant consideration. Anti-amyloid drugs can cause amyloid-related imaging abnormalities, including brain swelling and small areas of bleeding.
Although many cases are manageable, these complications require careful monitoring, particularly among patients with certain genetic risk factors. Treatment costs, accessibility and the need for repeated medical assessments also present challenges.
The research represents a promising shift from treating established dementia towards identifying and addressing the disease before substantial damage occurs.
Large-scale clinical trials, long-term monitoring and improved diagnostic technologies will be essential to determine whether this strategy can deliver lasting protection.
For millions of families, even delaying Alzheimer’s by several years could make an enormous difference, preserving independence, relationships and quality of life.
If future studies demonstrate that anti-amyloid treatments can prevent or substantially postpone the disease, the implications for healthcare systems and ageing populations could be profound.
For now, scientists remain cautious. It is too early to declare Alzheimer’s preventable or curable, but the possibility of changing its trajectory offers renewed hope in a field that has struggled for decades to find effective treatments.